PROACT - Preventing cardiac damage in patients treated for breast cancer and lymphoma: a phase 3 Randomised, Open label, blinded endpoint, superiority trial of enalapril to prevent Anthracycline-induced CardioToxicity

• Status: Recruiting
• Sponsor: South Tees NHS Hospitals Foundation Trust
• Funder: NIHR RfPB
• Therapeutic area: Cardiovascular and Cancer
• Type of study: CTIMP

Aim: Can the ACEi Enalapril prevent anthracycline-induced cardiotoxicity in patient treated for breast cancer or Non Hodgkin lymphoma.

Primary outcome: The presence (≥14ng/L) or absence of cardiac troponin T (<14ng/L) release at any time during anthracycline treatment, and one month after the last dose of anthracycline.

• Clinical Phase: III
• Population: Adults
• Design: RCT
• Setting: Secondary Care
• Planned Sample Size: 170